ABCL
AbCellera Biologics Inc.
Price Chart
Latest Quote
$3.50
Current Price| Previous Close | $3.62 |
| Open | $3.57 |
| Day High | $3.65 |
| Day Low | $3.50 |
| Volume | 6,092,158 |
Stock Information
| Shares Outstanding | 299.34M |
| Total Debt | $142.22M |
| Cash Equivalents | $495.67M |
| Revenue | $35.33M |
| Net Income | $-171.68M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.05B |
| EPS (TTM) | $-0.57 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 9/42| Debt to Equity | 0.06 |
| Debt to Earnings | 2.27 |
| Current Ratio | 9.81 |
| Quick Ratio | 9.37 |
| Avg Revenue Growth | -23.08% |
| Profit Margin | -564.83% |
| Return on Equity | -15.42% |
| Avg FCF Growth | -50.11% |
| FCF Yield | -17.84% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $3.50 | 6,110,464 |
| 2026-01-30 | $3.62 | 4,309,000 |
| 2026-01-29 | $3.86 | 2,437,700 |
| 2026-01-28 | $3.90 | 3,008,400 |
| 2026-01-27 | $3.99 | 3,223,400 |
| 2026-01-26 | $4.14 | 4,388,300 |
| 2026-01-23 | $4.24 | 5,803,000 |
| 2026-01-22 | $4.64 | 6,992,100 |
| 2026-01-21 | $4.28 | 3,902,200 |
| 2026-01-20 | $4.16 | 3,872,400 |
| 2026-01-16 | $4.12 | 5,389,800 |
| 2026-01-15 | $4.18 | 5,318,600 |
| 2026-01-14 | $4.29 | 4,095,200 |
| 2026-01-13 | $4.27 | 7,036,600 |
| 2026-01-12 | $4.52 | 5,054,800 |
| 2026-01-09 | $4.37 | 6,462,800 |
| 2026-01-08 | $4.11 | 4,806,500 |
| 2026-01-07 | $4.13 | 5,813,600 |
| 2026-01-06 | $3.90 | 6,359,100 |
| 2026-01-05 | $3.43 | 3,731,400 |
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
📰 Latest News
AbCellera’s ABCL635 Phase 2 Start Highlights Menopause Focus And Valuation Gap
Simply Wall St. • 2026-01-31T05:09:13Z
AbCellera Biologics (ABCL) Valuation Check After Mixed Long Term Shareholder Returns
Simply Wall St. • 2026-01-30T13:13:53Z
Reassessing AbCellera Biologics (ABCL) After A Sharp 16.8% Weekly Share Price Drop
Simply Wall St. • 2026-01-30T06:17:07Z
What Does Wall Street Think About AbCellera Biologics Inc. (ABCL)?
Insider Monkey • 2026-01-29T18:49:00Z
AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026
MarketBeat • 2026-01-15T01:07:03Z
3 Promising Penny Stocks With Market Caps Under $2B
Simply Wall St. • 2026-01-07T12:05:31Z
We're Not Worried About AbCellera Biologics' (NASDAQ:ABCL) Cash Burn
Simply Wall St. • 2025-12-25T13:05:56Z
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires • 2025-12-18T20:55:46ZAbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results
Insider Monkey • 2025-12-05T03:09:50Z
SunCar Technology Group And 2 Other Penny Stocks To Consider
Simply Wall St. • 2025-11-28T12:04:54Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $0 | $0 | $61,177,000 | $42,717,000 |
| Cost Of Revenue | $0 | $0 | $66,436,000 | $45,516,000 |
| Total Revenue | $28,833,000 | $38,025,000 | $485,424,000 | $375,203,000 |
| Operating Revenue | $28,833,000 | $38,025,000 | $485,424,000 | $375,203,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $329,979,000 | $261,077,000 | $258,359,000 | $153,304,000 |
| Other Income Expense | $62,278,000 | $6,776,000 | $-4,045,000 | $-6,080,000 |
| Other Non Operating Income Expenses | $62,278,000 | $6,776,000 | $-4,045,000 | $-6,080,000 |
| Net Non Operating Interest Income Expense | $38,473,000 | $42,247,000 | $16,079,000 | $3,330,000 |
| Operating Expense | $329,979,000 | $261,077,000 | $191,923,000 | $107,788,000 |
| Other Operating Expenses | $-13,620,000 | $-14,155,000 | $-10,554,000 | $-17,486,000 |
| Selling And Marketing Expense | $12,779,000 | $14,180,000 | $11,270,000 | $6,913,000 |
| General And Administrative Expense | $72,711,000 | $60,999,000 | $55,485,000 | $41,848,000 |
| Interest Expense | - | - | $4,045,000 | $5,225,000 |
| Interest Expense Non Operating | - | - | $4,045,000 | $5,225,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-162,857,000 | $-146,398,000 | $158,519,000 | $153,464,000 |
| Net Interest Income | $38,473,000 | $42,247,000 | $16,079,000 | $3,330,000 |
| Interest Income | $38,473,000 | $42,247,000 | $16,079,000 | $3,330,000 |
| Normalized Income | $-162,857,000 | $-146,398,000 | $158,519,000 | $153,464,000 |
| Net Income From Continuing And Discontinued Operation | $-162,857,000 | $-146,398,000 | $158,519,000 | $153,464,000 |
| Total Operating Income As Reported | $-314,766,000 | $-237,207,000 | $216,511,000 | $204,413,000 |
| Net Income Common Stockholders | $-162,857,000 | $-146,398,000 | $158,519,000 | $153,464,000 |
| Net Income | $-162,857,000 | $-146,398,000 | $158,519,000 | $153,464,000 |
| Net Income Including Noncontrolling Interests | $-162,857,000 | $-146,398,000 | $158,519,000 | $153,464,000 |
| Net Income Continuous Operations | $-162,857,000 | $-146,398,000 | $158,519,000 | $153,464,000 |
| Pretax Income | $-200,395,000 | $-174,029,000 | $239,099,000 | $219,149,000 |
| Interest Income Non Operating | $38,473,000 | $42,247,000 | $16,079,000 | $3,330,000 |
| Operating Income | $-301,146,000 | $-223,052,000 | $227,065,000 | $221,899,000 |
| Depreciation Amortization Depletion Income Statement | $90,850,000 | $24,395,000 | $27,843,000 | $14,451,000 |
| Depreciation And Amortization In Income Statement | $90,850,000 | $24,395,000 | $27,843,000 | $14,451,000 |
| Gross Profit | $28,833,000 | $38,025,000 | $418,988,000 | $329,687,000 |
| Depreciation Income Statement | - | - | $27,843,000 | $14,451,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-0.55 | $-0.51 | $0.50 | $0.48 |
| Basic EPS | $-0.55 | $-0.51 | $0.56 | $0.56 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-204,148,000 | $-192,158,000 | $260,167,000 | $239,149,000 |
| Reconciled Depreciation | $96,998,000 | $30,894,000 | $33,102,000 | $17,250,000 |
| EBITDA (Bullshit earnings) | $-204,148,000 | $-192,158,000 | $260,167,000 | $239,149,000 |
| EBIT | $-301,146,000 | $-223,052,000 | $227,065,000 | $221,899,000 |
| Diluted Average Shares | $294,327,532 | $289,166,486 | $314,827,255 | $318,294,236 |
| Basic Average Shares | $294,327,532 | $289,166,486 | $285,056,606 | $275,763,745 |
| Diluted NI Availto Com Stockholders | $-162,857,000 | $-146,398,000 | $158,519,000 | $153,464,000 |
| Tax Provision | $-37,538,000 | $-27,631,000 | $80,580,000 | $65,685,000 |
| Research And Development | $167,259,000 | $175,658,000 | $107,879,000 | $62,062,000 |
| Selling General And Administration | $85,490,000 | $75,179,000 | $66,755,000 | $48,761,000 |
| Other Gand A | $72,711,000 | $60,999,000 | $55,485,000 | $41,848,000 |
| Otherunder Preferred Stock Dividend | - | - | $0 | $0 |
| Total Unusual Items | - | - | - | $-855,000 |
| Total Unusual Items Excluding Goodwill | - | - | - | $-855,000 |
| Gain On Sale Of Security | - | - | - | $-855,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $966,165,000 | $984,087,000 | $1,053,969,000 | $829,535,000 |
| Total Assets | $1,360,553,000 | $1,488,094,000 | $1,540,907,000 | $1,318,569,000 |
| Total Non Current Assets | $609,183,000 | $616,109,000 | $515,416,000 | $388,769,000 |
| Other Non Current Assets | $96,538,000 | $94,244,000 | $46,331,000 | $30,642,000 |
| Goodwill And Other Intangible Assets | $89,919,000 | $168,231,000 | $179,308,000 | $196,198,000 |
| Other Intangible Assets | $42,113,000 | $120,425,000 | $131,502,000 | $148,392,000 |
| Current Assets | $751,370,000 | $871,985,000 | $1,025,491,000 | $929,800,000 |
| Other Current Assets | $8,626,000 | $22,018,000 | $9,064,000 | - |
| Restricted Cash | $25,000,000 | $25,000,000 | $25,000,000 | $25,000,000 |
| Receivables | $92,130,000 | $64,382,000 | $103,410,000 | $174,858,000 |
| Taxes Receivable | $26,534,000 | $33,792,000 | $64,817,000 | $14,282,000 |
| Loans Receivable | $31,980,000 | $0 | - | - |
| Accounts Receivable | $33,616,000 | $30,590,000 | $38,593,000 | $160,576,000 |
| Cash Cash Equivalents And Short Term Investments | $625,614,000 | $760,585,000 | $886,485,000 | $722,977,000 |
| Cash And Cash Equivalents | $156,325,000 | $133,320,000 | $386,535,000 | $476,142,000 |
| Inventory | - | $1,107,000 | $1,532,000 | $1,672,000 |
| Prepaid Assets | - | - | $9,064,000 | $5,293,000 |
| Non Current Prepaid Assets | - | - | - | $16,470,000 |
| Non Current Deferred Assets | - | - | - | $7,408,000 |
| Non Current Deferred Taxes Assets | - | - | - | $7,408,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $65,364,000 | $77,380,000 | $82,258,000 | $40,065,000 |
| Long Term Debt And Capital Lease Obligation | $60,743,000 | $71,222,000 | $76,675,000 | $36,413,000 |
| Current Debt And Capital Lease Obligation | $4,621,000 | $6,158,000 | $5,583,000 | $3,652,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $304,469,000 | $335,776,000 | $307,630,000 | $292,836,000 |
| Total Non Current Liabilities Net Minority Interest | $227,857,000 | $216,763,000 | $189,310,000 | $172,160,000 |
| Other Non Current Liabilities | $1,469,000 | $5,906,000 | $3,086,000 | $1,733,000 |
| Tradeand Other Payables Non Current | $0 | $4,913,000 | $16,054,000 | $35,886,000 |
| Non Current Deferred Liabilities | $165,645,000 | $134,722,000 | $93,495,000 | $98,128,000 |
| Non Current Deferred Taxes Liabilities | $10,052,000 | $30,612,000 | $33,178,000 | $37,370,000 |
| Current Liabilities | $76,612,000 | $119,013,000 | $118,320,000 | $120,676,000 |
| Current Deferred Liabilities | $21,179,000 | $26,070,000 | $27,897,000 | $12,009,000 |
| Payables And Accrued Expenses | $50,812,000 | $86,785,000 | $84,840,000 | $100,082,000 |
| Payables | $42,437,000 | $79,078,000 | $78,386,000 | $96,047,000 |
| Other Payable | $8,087,000 | $50,475,000 | $63,558,000 | $45,440,000 |
| Accounts Payable | $34,350,000 | $28,603,000 | $14,828,000 | $14,924,000 |
| Total Tax Payable | - | - | $0 | $35,683,000 |
| Income Tax Payable | - | - | $0 | $35,683,000 |
| Other Current Liabilities | - | - | - | $4,933,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $1,056,084,000 | $1,152,318,000 | $1,233,277,000 | $1,025,733,000 |
| Total Equity Gross Minority Interest | $1,056,084,000 | $1,152,318,000 | $1,233,277,000 | $1,025,733,000 |
| Stockholders Equity | $1,056,084,000 | $1,152,318,000 | $1,233,277,000 | $1,025,733,000 |
| Gains Losses Not Affecting Retained Earnings | $-4,378,000 | $-1,720,000 | $-1,391,000 | $280,000 |
| Other Equity Adjustments | $-4,378,000 | $-1,720,000 | $-1,391,000 | $280,000 |
| Retained Earnings | $116,930,000 | $279,787,000 | $426,185,000 | $267,666,000 |
| Long Term Equity Investment | $82,297,000 | $65,938,000 | $72,522,000 | $50,313,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $295,757,002 | $290,824,970 | $286,851,595 | $283,257,104 |
| Share Issued | $295,757,002 | $290,824,970 | $286,851,595 | $283,257,104 |
| Tangible Book Value | $966,165,000 | $984,087,000 | $1,053,969,000 | $829,535,000 |
| Invested Capital | $1,056,084,000 | $1,152,318,000 | $1,233,277,000 | $1,025,733,000 |
| Working Capital | $674,758,000 | $752,972,000 | $907,171,000 | $809,124,000 |
| Capital Lease Obligations | $65,364,000 | $77,380,000 | $82,258,000 | $40,065,000 |
| Total Capitalization | $1,056,084,000 | $1,152,318,000 | $1,233,277,000 | $1,025,733,000 |
| Additional Paid In Capital | $166,361,000 | $121,052,000 | $74,118,000 | $35,357,000 |
| Capital Stock | $777,171,000 | $753,199,000 | $734,365,000 | $722,430,000 |
| Common Stock | $777,171,000 | $753,199,000 | $734,365,000 | $722,430,000 |
| Non Current Deferred Revenue | $155,593,000 | $104,110,000 | $60,317,000 | $60,758,000 |
| Long Term Capital Lease Obligation | $60,743,000 | $71,222,000 | $76,675,000 | $36,413,000 |
| Current Deferred Revenue | $21,179,000 | $26,070,000 | $27,897,000 | $12,009,000 |
| Current Capital Lease Obligation | $4,621,000 | $6,158,000 | $5,583,000 | $3,652,000 |
| Current Accrued Expenses | $8,375,000 | $7,707,000 | $6,454,000 | $4,035,000 |
| Investments And Advances | $82,297,000 | $65,938,000 | $72,522,000 | $50,313,000 |
| Goodwill | $47,806,000 | $47,806,000 | $47,806,000 | $47,806,000 |
| Net PPE | $340,429,000 | $287,696,000 | $217,255,000 | $111,616,000 |
| Accumulated Depreciation | $-39,718,000 | $-30,608,000 | $-18,475,000 | $-9,826,000 |
| Gross PPE | $380,147,000 | $318,304,000 | $235,730,000 | $121,442,000 |
| Leases | $122,892,000 | $73,944,000 | $40,567,000 | $22,750,000 |
| Other Properties | $150,937,000 | $147,008,000 | $122,094,000 | $56,593,000 |
| Buildings And Improvements | $52,913,000 | $43,947,000 | $11,361,000 | $1,212,000 |
| Land And Improvements | $53,405,000 | $53,405,000 | $53,405,000 | $33,044,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $469,289,000 | $627,265,000 | $499,950,000 | $246,835,000 |
| Machinery Furniture Equipment | - | $3,517,000 | $8,303,000 | $7,843,000 |
| Raw Materials | - | $1,107,000 | $1,532,000 | $1,672,000 |
| Other Investments | - | - | - | $6,764,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-186,952,000 | $-121,384,000 | $204,700,000 | $186,132,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-108,556,000 | $-43,877,000 | $277,360,000 | $244,584,000 |
| Cash Flow From Continuing Operating Activities | $-108,556,000 | $-43,877,000 | $277,360,000 | $244,584,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-78,396,000 | $-77,507,000 | $-72,660,000 | $-58,452,000 |
| Investing Cash Flow | $121,409,000 | $-221,108,000 | $-352,625,000 | $-332,247,000 |
| Cash Flow From Continuing Investing Activities | $121,409,000 | $-221,108,000 | $-352,625,000 | $-332,247,000 |
| Net Other Investing Changes | $35,708,000 | $25,311,000 | $16,434,000 | $32,621,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Financing Cash Flow | $12,769,000 | $10,356,000 | $-1,628,000 | $-3,886,000 |
| Cash Flow From Continuing Financing Activities | $12,769,000 | $10,356,000 | $-1,628,000 | $-3,886,000 |
| Net Other Financing Charges | $12,769,000 | $10,356,000 | $-1,628,000 | $-9,373,000 |
| Issuance Of Capital Stock | - | - | $0 | $0 |
| Net Preferred Stock Issuance | - | - | $0 | $0 |
| Preferred Stock Issuance | - | - | $0 | $0 |
| Net Common Stock Issuance | - | - | $0 | $0 |
| Common Stock Issuance | - | - | $0 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| End Cash Position | $183,615,000 | $160,610,000 | $414,650,000 | $501,142,000 |
| Beginning Cash Position | $160,610,000 | $414,650,000 | $501,142,000 | $594,116,000 |
| Effect Of Exchange Rate Changes | $-2,617,000 | $589,000 | $-9,599,000 | $-1,425,000 |
| Changes In Cash | $25,622,000 | $-254,629,000 | $-76,893,000 | $-91,549,000 |
| Net Investment Purchase And Sale | $183,723,000 | $-155,222,000 | $-270,720,000 | $-264,636,000 |
| Sale Of Investment | $948,809,000 | $910,937,000 | $510,631,000 | $27,608,000 |
| Purchase Of Investment | $-765,086,000 | $-1,066,159,000 | $-781,351,000 | $-292,244,000 |
| Net Business Purchase And Sale | $-19,626,000 | $-13,690,000 | $-25,679,000 | $-41,780,000 |
| Purchase Of Business | $-19,626,000 | $-13,690,000 | $-25,679,000 | $-41,780,000 |
| Net Intangibles Purchase And Sale | $0 | $-560,000 | $-2,000,000 | $0 |
| Purchase Of Intangibles | $0 | $-560,000 | $-2,000,000 | $0 |
| Net PPE Purchase And Sale | $-78,396,000 | $-76,947,000 | $-70,660,000 | $-58,452,000 |
| Purchase Of PPE | $-78,396,000 | $-76,947,000 | $-70,660,000 | $-58,452,000 |
| Change In Working Capital | $-25,843,000 | $13,225,000 | $29,825,000 | $41,672,000 |
| Change In Other Working Capital | $32,687,000 | $56,009,000 | $-73,162,000 | $25,812,000 |
| Change In Other Current Assets | $5,954,000 | $8,980,000 | $-1,375,000 | $-3,381,000 |
| Change In Payables And Accrued Expense | $10,635,000 | $-15,104,000 | $-2,094,000 | $-3,237,000 |
| Change In Receivables | $-75,119,000 | $-36,660,000 | $106,456,000 | $22,478,000 |
| Changes In Account Receivables | $-75,119,000 | $-45,933,000 | $-22,715,000 | $-37,386,000 |
| Other Non Cash Items | $-84,435,000 | $-5,781,000 | $6,433,000 | $3,570,000 |
| Stock Based Compensation | $67,581,000 | $64,183,000 | $49,481,000 | $30,646,000 |
| Depreciation Amortization Depletion | $96,998,000 | $30,894,000 | $33,102,000 | $17,250,000 |
| Depreciation And Amortization | $96,998,000 | $30,894,000 | $33,102,000 | $17,250,000 |
| Amortization Cash Flow | $78,312,000 | $11,637,000 | $18,890,000 | $10,062,000 |
| Amortization Of Intangibles | $78,312,000 | $11,637,000 | $18,890,000 | $10,062,000 |
| Depreciation | $18,686,000 | $19,257,000 | $14,212,000 | $7,188,000 |
| Net Income From Continuing Operations | $-162,857,000 | $-146,398,000 | $158,519,000 | $153,464,000 |
| Issuance Of Debt | - | $11,590,000 | $2,755,000 | $5,487,000 |
| Net Issuance Payments Of Debt | - | $11,590,000 | $2,432,000 | $5,487,000 |
| Net Long Term Debt Issuance | - | $11,590,000 | $2,432,000 | $5,487,000 |
| Long Term Debt Issuance | - | $11,590,000 | $2,755,000 | $5,487,000 |
| Change In Payable | - | $-15,104,000 | $-87,543,000 | $-3,237,000 |
| Change In Account Payable | - | $-15,104,000 | $1,066,000 | $-3,237,000 |
| Deferred Tax | - | $1,960,000 | $-2,114,000 | $-2,018,000 |
| Deferred Income Tax | - | $1,960,000 | $-2,114,000 | $-2,018,000 |
| Repayment Of Debt | - | - | $-323,000 | $-1,823,000 |
| Long Term Debt Payments | - | - | $-323,000 | $-1,823,000 |
| Change In Other Current Liabilities | - | - | $-3,064,000 | $-778,000 |
| Change In Accrued Expense | - | - | $-3,160,000 | $-4,637,000 |
| Change In Tax Payable | - | - | $-88,609,000 | $-13,530,000 |
| Change In Income Tax Payable | - | - | $-88,609,000 | $-13,530,000 |
| Proceeds From Stock Option Exercised | - | - | - | $4,615,000 |
| Net Short Term Debt Issuance | - | - | - | $0 |